Back to User profile » Prof. Dr. Peter Galle
Papers published by Prof. Dr. Peter Galle:
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
Stefanini B, Fulgenzi CAM, Scheiner B, Korolewicz J, Cheon J, Nishida N, Ang C, Marron TU, Wu YL, Saeed A, Wietharn B, Rimassa L, Pirozzi A, Cammarota A, Pressiani T, Pinter M, Balcar L, Huang YH, Mehan A, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Samson A, Galle PR, Kudo M, Manfredi GF, Celsa C, Awosika N, Cortellini A, Singal AG, Sharma R, Chon HJ, Tovoli F, Piscaglia F, Pinato DJ, D’Alessio A
Journal of Hepatocellular Carcinoma 2025, 12:671-683
Published Date: 4 April 2025
Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion
Kulik L, da Fonseca LG, He AR, Rimola J, Wilson Woods A, Zöllner YF, Galle PR
Journal of Hepatocellular Carcinoma 2020, 7:423-433
Published Date: 21 December 2020
Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort
Bernuth S, Grimm D, Vollmar J, Darstein F, Mittler J, Heise M, Hoppe-Lotichius M, Galle PR, Lang H, Zimmermann T
Drug Design, Development and Therapy 2017, 11:2131-2138
Published Date: 12 July 2017
Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells
Heinrich B, Goepfert K, Delic M, Galle PR, Moehler M
OncoTargets and Therapy 2013, 6:1119-1127
Published Date: 20 August 2013